593594 Disclosed are sulphonyl substituted benzylamides of formula (I) where the substituents are as disclosed in the specification. Examples of compounds of formula (I) are: 4-[4-(cyclohexylmethyl)-4-methoxypiperidin-1-yl]-N-{ [5-({ (1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl} amino)-4-nitrothien-2-yl]sulfonyl} benzamide N-{ [5-({ (1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl} amino)-4-nitrothien-2-yl]sulfonyl} -4-[4-methoxy-4-(3-methylbenzyl)piperidin-1-yl]benzamide N-{ [5-({ (1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl} amino)-4-nitrothien-2-yl]sulfonyl} -4-[4-(3,3-diphenylprop-2-enyl)piperazin-1-yl]benzamide and 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-N-({ 2-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-4-methyl-1,3-thiazol-5-yl} sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide. Further disclosed are the use of the compounds in the manufacture of a medicament for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancy of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer in a patient.
